Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
– Initiating Registrational Cohorts with Update on Path to Registration by Year-End 2024 –– Virtual Investor Event Today at 8:00 […]